Vor Biopharma (VOR) AI Stock Analysis

• Market Cap: $769.10M
• Dividend Yield: N/A
• Average Volume (3M): 1.01M
• Price to Earnings (P/E): <0.1
• Beta (1Y): 4.90
• Revenue Growth: N/A
• EPS Growth: -1072.48%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 52.28
• Shares Outstanding: 48,847,504
• 10 Day Avg. Volume: 1,277,895
• 30 Day Avg. Volume: 1,013,893
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.90
• Enterprise Value/Market Cap: -0.37
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 336.76
• Enterprise Value/Ebitda: 0.25
• 1Y Price Target: $37.00
• Price Target Upside: 135.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -3.64
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $17.50 ▲(11.18% Upside)
• Action: Reiterated Date: 04/01/26
• Date: Action: Reiterated 04/01/26

The score is held down primarily by weak financial performance (no revenue, heavier losses, persistent cash burn, and negative equity). Technicals are only modestly constructive (price above shorter-term averages but below the 200-day with slightly negative MACD), while valuation remains unattractive due to ongoing losses and no dividend. Corporate events provide some offset via fresh financing and continued clinical program progress.

Positive Factors

Established commercial footprint in China

Having an established commercial footprint and extensive clinical exposure in China via RemeGen materially de-risks global development and commercialization pathways. Durable safety and real-world treatment experience support regulatory discussions, payer engagement, and faster market access if Western approvals succeed.

Negative Factors

No revenue; sharply widening losses

The absence of product revenue combined with a dramatic increase in net loss to roughly -$696M indicates the company remains wholly pre-commercial and highly reliant on R&D spending. This structural loss profile requires repeated external funding and increases execution risk if clinical readouts falter.

Vor Biopharma Business Overview & Revenue Model

Company Description

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other...

Read more

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other...

How the Company Makes Money

Vor Biopharma does not have a stable, product-based commercial revenue stream because it is a clinical-stage company and its therapeutic candidates are not established as marketed products. As a result, the company’s ability to generate revenue is...

Read more

Vor Biopharma does not have a stable, product-based commercial revenue stream because it is a clinical-stage company and its therapeutic candidates are not established as marketed products. As a result, the company’s ability to generate revenue is...

Vor Biopharma Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-3.49M	-8.96M	0.00
EBITDA	-368.75M	-117.66M	-114.37M	-83.13M	-67.58M
Net Income	-695.98M	-116.91M	-117.86M	-92.09M	-68.90M
Balance Sheet
Total Assets	464.13M	142.89M	209.83M	299.37M	242.59M
Cash, Cash Equivalents and Short-Term Investments	455.21M	91.93M	137.18M	230.25M	207.47M
Total Debt	3.00M	31.83M	35.66M	38.91M	18.01M
Total Liabilities	628.44M	46.23M	59.10M	48.76M	26.33M
Stockholders Equity	-164.31M	96.66M	150.72M	250.61M	216.26M
Cash Flow
Free Cash Flow	-143.65M	-99.89M	-101.36M	-93.61M	-73.04M
Operating Cash Flow	-142.71M	-99.66M	-100.29M	-85.14M	-69.14M
Investing Cash Flow	-48.80M	96.86M	71.01M	-94.09M	-91.65M
Financing Cash Flow	503.81M	53.39M	2.94M	117.14M	232.91M

Vor Biopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Neutral. The current price of 15.74 is above the 20-day moving average (MA) of 14.54, above the 50-day MA of 14.28, and below the 200-day MA of 24.02, indicating a neutral trend. The MACD of 0.67 indicates Negative momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 53.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VOR.

Vor Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVIR	57 Neutral	$472.46M	-1.84	-46.34%	―	―	14.33%
BDTX	52 Neutral	$143.22M	6.18	17.46%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CDXS	50 Neutral	$200.82M	-3.23	-90.51%	―	-17.87%	14.42%
KYTX	50 Neutral	$557.26M	-2.58	-81.41%	―	―	-21.22%
VOR	47 Neutral	$769.10M	0.02	72.70%	―	―	-1072.48%
CRBU	47 Neutral	$188.44M	-1.42	-74.28%	―	-19.00%	-2.72%

Vor Biopharma Corporate Events